JP2012527875A5 - - Google Patents

Download PDF

Info

Publication number
JP2012527875A5
JP2012527875A5 JP2012512351A JP2012512351A JP2012527875A5 JP 2012527875 A5 JP2012527875 A5 JP 2012527875A5 JP 2012512351 A JP2012512351 A JP 2012512351A JP 2012512351 A JP2012512351 A JP 2012512351A JP 2012527875 A5 JP2012527875 A5 JP 2012527875A5
Authority
JP
Japan
Prior art keywords
binding protein
antigen
protein according
receptor
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012512351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012527875A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/057227 external-priority patent/WO2010136480A1/en
Publication of JP2012527875A publication Critical patent/JP2012527875A/ja
Publication of JP2012527875A5 publication Critical patent/JP2012527875A5/ja
Pending legal-status Critical Current

Links

JP2012512351A 2009-05-28 2010-05-26 抗原結合タンパク質 Pending JP2012527875A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18186509P 2009-05-28 2009-05-28
US61/181,865 2009-05-28
PCT/EP2010/057227 WO2010136480A1 (en) 2009-05-28 2010-05-26 Antigen-binding proteins

Publications (2)

Publication Number Publication Date
JP2012527875A JP2012527875A (ja) 2012-11-12
JP2012527875A5 true JP2012527875A5 (enExample) 2013-07-11

Family

ID=42332502

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012512351A Pending JP2012527875A (ja) 2009-05-28 2010-05-26 抗原結合タンパク質

Country Status (5)

Country Link
US (1) US20120070436A1 (enExample)
EP (1) EP2435477A1 (enExample)
JP (1) JP2012527875A (enExample)
CA (1) CA2763439A1 (enExample)
WO (1) WO2010136480A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014014418A2 (pt) * 2011-12-15 2019-09-24 Nat Res Council Canada proteínas de fusão fc de receptor igf solúvel e usos das mesmas
CN104159916A (zh) * 2012-02-22 2014-11-19 Nvip私人有限公司 肿瘤坏死因子受体融合蛋白及其使用方法
CN102585016B (zh) * 2012-03-06 2014-06-04 江苏健德生物药业有限公司 一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用
CN103045646B (zh) * 2012-12-27 2015-02-25 中国人民解放军军事医学科学院基础医学研究所 共表达两个独立的抗关节炎分子TNFR-Fc和CTLA4-FasL的重组腺相关病毒载体及其构建方法与应用
CN103232542B (zh) * 2013-02-01 2015-05-13 殷勇 一种双靶标嵌合蛋白
WO2014168715A1 (en) * 2013-04-08 2014-10-16 R-Pharm Overseas, Inc. B7 ligands/cd20 inhibitor composition and use thereof
CN104231086B (zh) * 2013-08-27 2019-12-13 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
KR20160113268A (ko) * 2014-01-28 2016-09-28 베이징 한미 파마슈티컬 컴퍼니 리미티드 이기능 융합단백질,이의 제조방법 및 용도
CN107074976B (zh) * 2014-11-04 2020-10-09 北京韩美药品有限公司 同时阻断b7/cd28和il6/il6r/gp130信号通路的重组融合蛋白
CN111423512B (zh) * 2019-01-10 2024-01-05 北京比洋生物技术有限公司 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
WO2021028837A1 (en) * 2019-08-13 2021-02-18 Waters Technologies Corporation Affinity resins and sample preparation devices based on cartilaginous fish ignar derived binding domains
CN115812077A (zh) 2020-05-08 2023-03-17 高山免疫科学股份有限公司 April和baff抑制性免疫调节蛋白及其使用方法
WO2024091723A1 (en) * 2022-10-25 2024-05-02 The Regents Of The University Of California Methods for sensitizing response to an immunotherapy
US12240888B1 (en) * 2024-04-29 2025-03-04 QILU Pharmaceutical, Co., Ltd. Composition comprising aflibercept and a variant thereof, and related methods and uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7255854B1 (en) * 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
IL129527A (en) * 1996-10-25 2006-12-10 Biogen Idec Inc Pharmaceutical preparations containing soluble lymphoxine-beta receptors
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion

Similar Documents

Publication Publication Date Title
JP2012527875A5 (enExample)
CN112480253B (zh) 一种抗pd-l1纳米抗体及其衍生物和用途
Beirnaert et al. Bivalent llama single-domain antibody fragments against tumor necrosis factor have picomolar potencies due to intramolecular interactions
HRP20150799T1 (hr) Sastavi i postupci za protutijela protiv komplementnog proteina c5
JP2012501669A5 (enExample)
JP2017008046A5 (enExample)
JP2021502810A5 (enExample)
JP2017079785A5 (enExample)
JP2016511277A5 (enExample)
JP2017522903A5 (enExample)
JP2012501670A5 (enExample)
JP2016507555A5 (enExample)
JP2012507994A5 (enExample)
JP2018529327A5 (enExample)
JP2012518398A5 (enExample)
HRP20190472T1 (hr) Klaudin-6 specifični imunoreceptori i t-stanični epitopi
JP2017529067A5 (enExample)
JP2014500009A5 (enExample)
JP2015508757A5 (enExample)
JP2013107899A5 (enExample)
JP2017532952A5 (enExample)
JP2018502060A5 (enExample)
JP2018512145A5 (enExample)
JP2018537421A5 (enExample)
RU2019115610A (ru) Антитела и полипептиды, направленные против cd127